Accure Therapeutics is a company that develops a drug candidate portfolio in three programs (ACT-01, ACT-02, ACT-03) pursuing innovative targets that focus on four areas: Optic Neuritis, Multiple Sclerosis, Parkinson’s Disease, and Epilepsy. It follows a straightforward corporate model, consisting of integrating valuable assets, people, R&D programs and investors to address the need for disease modifier medicines to treat CNS diseases.